Table 1. Correlations between the expression of EMX2OS/EMX2 and clinicopathologic characteristics in KIRC.
| Characteristic | n (%) | EMX2OS expression (%) | p-value* | EMX2 expression (%) | p-value* | ||
| High | Low | High | Low | ||||
| Total | 535 (100) | 267 (49.91) | 268 (50.09) | 267 (49.91) | 268 (50.09) | ||
| Age | 0.897 | 0.195 | |||||
| ≤ 60 years | 267 (49.91) | 132 (49.4) | 135 (50.4) | 141 (52.8) | 126 (47.0) | ||
| > 60 years | 268 (50.09) | 135 (50.6) | 133 (49.6) | 126 (47.2) | 142 (53.0) | ||
| Gender | 0.001 | 0.029 | |||||
| Female | 186 (34.77) | 111 (41.6) | 75 (28.0) | 105 (39.3) | 81 (30.2) | ||
| Male | 349 (65.23) | 156 (58.4) | 193 (72.0) | 162 (60.7) | 187 (69.8) | ||
| Cancer status | < 0.001 | < 0.001 | |||||
| Tumor free | 336 (62.8) | 186 (69.7) | 150 (56.0) | 186 (69.7) | 150 (56.0) | ||
| With tumor | 148 (27.66) | 47 (17.6) | 101 (37.7) | 48 (18.0) | 100 (37.3) | ||
| Unknow | 51 (9.53) | 34 (12.7) | 17 (6.3) | 33 (12.4) | 18 (6.7) | ||
| Race | 0.021 | 0.015 | |||||
| White | 463 (86.54) | 222 (83.1) | 241 (89.9) | 222 (83.1) | 241 (89.9) | ||
| Asian | 8 (1.5) | 5 (1.9) | 3 (1.1) | 4 (1.5) | 4 (1.5) | ||
| Black | 57 (10.65) | 38 (14.2) | 19 (7.1) | 39 (14.6) | 18 (6.7) | ||
| Unknow | 7 (1.31) | 2 (0.7) | 5 (1.9) | 2 (0.7) | 5 (1.9) | ||
| Grade | < 0.001 | < 0.001 | |||||
| G1 | 14 (2.62) | 13 (4.9) | 1 (0.4) | 13 (4.9) | 1 (0.4) | ||
| G2 | 231 (43.18) | 137 (51.3) | 94 (35.1) | 142 (53.2) | 89 (33.2) | ||
| G3 | 207 (38.69) | 100 (37.5) | 107 (39.9) | 93 (34.8) | 114 (42.5) | ||
| G4 | 75 (14.02) | 14 (5.2) | 61 (22.8) | 17 (6.4) | 58 (21.6) | ||
| Unknow | 8 (1.5) | 3 (1.1) | 5 (1.9) | 2 (0.7) | 6 (2.2) | ||
| T stage | < 0.001 | < 0.001 | |||||
| T1 | 275 (51.4) | 164 (61.4) | 111 (41.4) | 166 (62.2) | 109 (40.7) | ||
| T2 | 70 (13.08) | 32 (12.0) | 38 (14.2) | 31 (11.6) | 39 (14.6) | ||
| T3 | 179 (33.46) | 70 (26.2) | 109 (40.7) | 69 (25.8) | 110 (41.0) | ||
| T4 | 11 (2.06) | 1 (0.4) | 10 (3.7) | 1 (0.4) | 10 (3.7) | ||
| N stage | 0.008 | < 0.001 | |||||
| N0 | 240 (44.86) | 112 (41.9) | 128 (47.8) | 115 (43.1) | 125 (46.6) | ||
| N1 | 16 (2.99) | 2 (0.7) | 14 (5.2) | 0 (0.0) | 16 (6.0) | ||
| Unknow | 279 (52.15) | 153 (57.3) | 126 (47.0) | 152 (56.9) | 127 (47.4) | ||
| M stage | 0.001 | < 0.001 | |||||
| M0 | 424 (79.25) | 219 (82.0) | 205 (76.5) | 219 (82.0) | 205 (76.5) | ||
| M1 | 78 (14.58) | 24 (9.0) | 54 (20.1) | 23 (8.6) | 55 (20.5) | ||
| Unknow | 33 (6.17) | 24 (9.0) | 9 (3.4) | 25 (9.4) | 8 (3.0) | ||
| AJCC stage | < 0.001 | < 0.001 | |||||
| Stage I | 269 (50.28) | 163 (61.0) | 106 (39.6) | 164 (61.4) | 105 (39.2) | ||
| Stage II | 58 (10.84) | 28 (10.5) | 30 (11.2) | 26 (9.7) | 32 (11.9) | ||
| Stage III | 123 (22.99) | 51 (19.1) | 72 (26.9) | 51 (19.1) | 72 (26.9) | ||
| Stage IV | 82 (15.33) | 24 (9.0) | 58 (21.6) | 25 (9.4) | 57 (21.3) | ||
| Unknow | 3 (0.56) | 1 (0.4) | 2 (0.7) | 1 (0.4) | 2 (0.7) | ||
KIRC, Kidney renal clear cell carcinoma; AJCC, American Joint Committee on Cancer.
*Patients with the missing details were excluded when calculating the p value of the corresponding characteristic.